<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432273</url>
  </required_header>
  <id_info>
    <org_study_id>F-ZA113</org_study_id>
    <nct_id>NCT03432273</nct_id>
  </id_info>
  <brief_title>Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges</brief_title>
  <official_title>A Single-Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Two-Period Crossover Study to Determine the Bioequivalence of Two Nicotine Resinate Lozenge Formulations Containing Nicotine 2 mg in up to 42 Healthy Male and Female Smokers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertin Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertin Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess&#xD;
      bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy&#xD;
      smokers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve, from time zero to t, where t is the time of the last quantifiable concentration (AUC0-t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Time to maximum observed plasma concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve, with extrapolation to infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Terminal elimination rate constant (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½.z</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Apparent terminal elimination half-life (t½.z)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kel</measure>
    <time_frame>Blood samples taken pre-dose and post-dose at 5, 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 2, 3, 6, 9, 12, 16 and 24 hours</time_frame>
    <description>Apparent terminal elimination rate constant (kel)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Nicotine 2 mg mint lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NiQuitin 2 mg mint lozenges</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine lozenge</intervention_name>
    <description>Nicotine mint lozenge, 2 mg</description>
    <arm_group_label>Nicotine 2 mg mint lozenges</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine lozenge</intervention_name>
    <description>NiQuitin mint lozenge, 2 mg</description>
    <arm_group_label>NiQuitin 2 mg mint lozenges</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written consent given for participation in the study.&#xD;
&#xD;
          2. Healthy males and females, 18 to 55 years (inclusive) at screening.&#xD;
&#xD;
          3. Body Mass Index (BMI) between 18.5 and 30 kg/m2 (both inclusive).&#xD;
&#xD;
          4. Body mass not less than 50 kg.&#xD;
&#xD;
          5. Medical history, vital signs, physical examination, standard 12-lead electrocardiogram&#xD;
             (ECG) and laboratory investigations must be clinically acceptable or within laboratory&#xD;
             reference ranges for the relevant laboratory tests, unless the investigator considers&#xD;
             the deviation to be irrelevant for the purpose of the study.&#xD;
&#xD;
          6. Females, if:&#xD;
&#xD;
               -  Not of childbearing potential, e.g., has been surgically sterilized, undergone a&#xD;
                  hysterectomy, amenorrhea for ≥ 12 months and considered post-menopausal, Note: in&#xD;
                  postmenopausal women, the value of the serum pregnancy test may be slightly&#xD;
                  increased. This test will be repeated to confirm the results. If there is no&#xD;
                  increase indicative of pregnancy, the female will be included in the study.&#xD;
&#xD;
               -  Of childbearing potential, the following conditions are to be met:&#xD;
&#xD;
             Negative pregnancy test&#xD;
&#xD;
             If this test is positive, the subject will be excluded from the study. In the rare&#xD;
             circumstance that a pregnancy is discovered after the subject received IMP, every&#xD;
             attempt must be made to follow her to term.&#xD;
&#xD;
             Not lactating&#xD;
&#xD;
             Abstaining from sexual activity (if this is the usual lifestyle of the subject) or&#xD;
             must agree to use an accepted method of contraception, and agree to continue with the&#xD;
             same method throughout the study Examples of reliable methods of contraception include&#xD;
             oral (documented that the dose has been stable for at least one month before the first&#xD;
             intake of IMP), injectable or implantable contraceptives and non-hormonal intrauterine&#xD;
             device.&#xD;
&#xD;
             In this study the concomitant use of hormonal contraceptives is allowed. Other&#xD;
             methods, if considered by the investigator as reliable, will be accepted.&#xD;
&#xD;
          7. History of cigarette smoking of at least 10 cigarettes per day continuously for the&#xD;
             past 3 months prior to screening and smokes first cigarette in more than 30 minutes&#xD;
             after waking up in the morning.&#xD;
&#xD;
          8. No use of any tobacco or nicotine-containing products within 21 days of the first dose&#xD;
             except cigarettes.&#xD;
&#xD;
          9. Have no interest in quitting smoking.&#xD;
&#xD;
         10. Have accepted to refrain from smoking for the duration of the study periods.&#xD;
&#xD;
         11. Exhaled CO concentration &gt; 10 ppm at screening.&#xD;
&#xD;
         12. Successfully completed the dissolution training session prior to randomization.&#xD;
&#xD;
         13. Ability to communicate and comply with all study requirements including the study&#xD;
             specific method of administration for the nicotine lozenges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional&#xD;
             or intellectual problems likely to limit the validity of consent to participate in the&#xD;
             study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          2. Any surgical or medical condition which may significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of any IMP substance.&#xD;
&#xD;
          3. Current alcohol use &gt; 21 units of alcohol per week for males and &gt; 14 units of alcohol&#xD;
             per week for females or evidence of excessive alcohol use as indicated by an alcohol&#xD;
             breathalyzer test result ≥ 0.01%.&#xD;
&#xD;
          4. Regular exposure to substances of abuse (other than alcohol) within the past year.&#xD;
&#xD;
          5. Use of any medication, prescribed or over-the-counter or herbal remedies, within 2&#xD;
             weeks before the first administration of IMP except if this will not affect the&#xD;
             outcome of the study in the opinion of the investigator.&#xD;
&#xD;
             In this study the concomitant use of hormonal contraceptives is allowed.&#xD;
&#xD;
          6. Expired CO levels greater than 10 ppm in the morning prior to dosing.&#xD;
&#xD;
          7. History of esophagitis, gastritis, peptic ulcer, gastro-esophageal reflux,&#xD;
             gastrointestinal bleeding, rectal bleeding or other clinically significant&#xD;
             gastrointestinal abnormalities within past 3 months.&#xD;
&#xD;
          8. History of cardiovascular disease such as uncontrolled hypertension, myocardial&#xD;
             infarction, stroke or transient ischemic attack within the past 6 months prior to&#xD;
             screening, congestive heart failure, angina pectoris, and arrhythmia.&#xD;
&#xD;
          9. Evidence of vasospastic disease (i.e., Buerger's disease) on medical history and&#xD;
             physical examination.&#xD;
&#xD;
         10. Unable or unwilling to abstain from methylxanthines for 72 hours pre-dose.&#xD;
&#xD;
         11. Participation in another study with an experimental drug, where the last&#xD;
             administration of the previous IMP was within 8 weeks (or within 5 elimination&#xD;
             half-lives for chemical entities or 2 elimination half-lives for antibodies or&#xD;
             insulin, whichever is the longer) before administration of IMP in this study, at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
         12. Treatment within the previous 3 months before the first administration of IMP with any&#xD;
             drug with a well-defined potential for adversely affecting a major organ or system.&#xD;
&#xD;
         13. A major illness during the 3 months before commencement of the screening period.&#xD;
&#xD;
         14. History of hypersensitivity or allergy to the IMP or its excipients or any related&#xD;
             medication.&#xD;
&#xD;
         15. History of bronchial asthma or any other bronchospastic disease.&#xD;
&#xD;
         16. History of convulsions.&#xD;
&#xD;
         17. History of porphyria.&#xD;
&#xD;
         18. Relevant history or laboratory or clinical findings indicative of acute or chronic&#xD;
             disease, likely to influence study outcome.&#xD;
&#xD;
         19. Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the&#xD;
             first administration of IMP.&#xD;
&#xD;
         20. Diagnosis of hypotension made during the screening period.&#xD;
&#xD;
         21. Diagnosis of hypertension made during the screening period or current diagnosis of&#xD;
             hypertension.&#xD;
&#xD;
         22. Resting pulse of &gt; 100 beats per minute or &lt; 40 beats per minute during the screening&#xD;
             period, either supine or standing.&#xD;
&#xD;
         23. Positive testing for HIV, Hepatitis B and Hepatitis C.&#xD;
&#xD;
         24. Positive urine screen for drugs of abuse. In case of a positive result the urine&#xD;
             screen for drugs of abuse may be repeated once at the discretion of the investigator.&#xD;
&#xD;
         25. Positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolandi Swart, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL (South Africa)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

